EP1071465A1 - Amorphous glasses for stabilising sensitive products - Google Patents
Amorphous glasses for stabilising sensitive productsInfo
- Publication number
- EP1071465A1 EP1071465A1 EP99910516A EP99910516A EP1071465A1 EP 1071465 A1 EP1071465 A1 EP 1071465A1 EP 99910516 A EP99910516 A EP 99910516A EP 99910516 A EP99910516 A EP 99910516A EP 1071465 A1 EP1071465 A1 EP 1071465A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- mannitol
- drying
- glass
- compound
- inositol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000011521 glass Substances 0.000 title claims abstract description 46
- 230000003019 stabilising effect Effects 0.000 title description 10
- 239000000203 mixture Substances 0.000 claims abstract description 34
- 238000001035 drying Methods 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 17
- 239000000654 additive Substances 0.000 claims abstract description 14
- -1 monosaccharide sugar alcohols Chemical class 0.000 claims abstract description 11
- 230000000996 additive effect Effects 0.000 claims abstract description 10
- 239000013078 crystal Substances 0.000 claims abstract description 7
- 230000009849 deactivation Effects 0.000 claims abstract description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 58
- 229930195725 Mannitol Natural products 0.000 claims description 58
- 239000000594 mannitol Substances 0.000 claims description 58
- 235000010355 mannitol Nutrition 0.000 claims description 58
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 25
- 239000001527 calcium lactate Substances 0.000 claims description 25
- 229960002401 calcium lactate Drugs 0.000 claims description 25
- 235000011086 calcium lactate Nutrition 0.000 claims description 25
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 22
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 22
- 229960000367 inositol Drugs 0.000 claims description 22
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 22
- 238000009472 formulation Methods 0.000 claims description 20
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 claims description 13
- 150000005846 sugar alcohols Chemical class 0.000 claims description 11
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 10
- 238000004108 freeze drying Methods 0.000 claims description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- 239000000811 xylitol Substances 0.000 claims description 5
- 235000010447 xylitol Nutrition 0.000 claims description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
- 229960002675 xylitol Drugs 0.000 claims description 5
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- 229920003081 Povidone K 30 Polymers 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 102000034287 fluorescent proteins Human genes 0.000 claims description 3
- 108091006047 fluorescent proteins Proteins 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- GDTSJMKGXGJFGQ-UHFFFAOYSA-N 3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical class O1B([O-])OB2OB([O-])OB1O2 GDTSJMKGXGJFGQ-UHFFFAOYSA-N 0.000 claims description 2
- 159000000021 acetate salts Chemical class 0.000 claims description 2
- 229940063013 borate ion Drugs 0.000 claims description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 2
- 239000004327 boric acid Substances 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 229940124856 vaccine component Drugs 0.000 claims 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 239000000378 calcium silicate Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 37
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 37
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 37
- 235000000346 sugar Nutrition 0.000 description 21
- 239000000126 substance Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 239000003381 stabilizer Substances 0.000 description 14
- 150000008163 sugars Chemical class 0.000 description 11
- 239000000463 material Substances 0.000 description 8
- 108010010803 Gelatin Proteins 0.000 description 7
- 239000008273 gelatin Substances 0.000 description 7
- 229920000159 gelatin Polymers 0.000 description 7
- 235000019322 gelatine Nutrition 0.000 description 7
- 235000011852 gelatine desserts Nutrition 0.000 description 7
- 238000007496 glass forming Methods 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 230000001603 reducing effect Effects 0.000 description 7
- 230000006641 stabilisation Effects 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- 102000003951 Erythropoietin Human genes 0.000 description 5
- 108090000394 Erythropoietin Proteins 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 229940105423 erythropoietin Drugs 0.000 description 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000009477 glass transition Effects 0.000 description 4
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 238000005057 refrigeration Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical class N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004111 Potassium silicate Chemical class 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 239000004115 Sodium Silicate Chemical class 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 102100029677 Trehalase Human genes 0.000 description 1
- 108010087472 Trehalase Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- FZQSLXQPHPOTHG-UHFFFAOYSA-N [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 Chemical compound [K+].[K+].O1B([O-])OB2OB([O-])OB1O2 FZQSLXQPHPOTHG-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000009932 biopreservation Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 102000043557 human IFNG Human genes 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019353 potassium silicate Nutrition 0.000 description 1
- 229910052913 potassium silicate Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000002683 reaction inhibitor Substances 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical class [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 229910052911 sodium silicate Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/37—Sugar alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Definitions
- a common reactivity of sugar glasses is the reducing action of the carbonyl group and the degradation products formed are often the familiar carbonyl-amine compounds of the Maillard reaction (Ellis G.P. The Maillard reaction. Adv. Carbohyd. Chem. 14 63-134 (1959)). Because the Maillard reaction is temperature dependent, it is only slowly progressive at low temperatures. Many glass-forming materials give excellent preservation of activity during the drying process itself but the product subsequently undergoes progressive deterioration unless stored under refrigeration.
- trehalose Because it is subsequently degraded in the body by the specific enzyme, trehalase, to two molecules of glucose, trehalose possesses many of the properties of the ideal industrial stabiliser for foods and medical products.
- a large scientific and patent literature has now developed on trehalose stabilisation of foods, vaccines, diagnostics and drugs.
- the disadvantages of trehalose are that it is as yet not approved by the regulatory authorities, it is expensive and it contains contaminating reducing sugars, especially glucose, in all but the most rigorously purified material.
- the effect of these substances is dose dependent and below a threshold concentration they do not work.
- the substances useful in accordance with this invention promote the drying of mannitol solutions as glasses rather than crystals.
- One of the most potent materials is the borate ion either as boric acid, or tetraborate salts of sodium or potassium. This probably forms a network complex with mannitol or even a covalent compound, sodium mannitoborate.
- the quality of the glasses made by this process is high.
- the glass transition temperature (Tg) of 1 :1 w/w mannitol/calcium lactate glass is around 68°C ( Figure 1). This compares with a Tg of around 90°C for a trehalose/sodium sulphate glass dried under the same conditions ( Figure 2). Both types of glass have Tg's well above any possible ambient storage temperature and, because the glasses are chemically inert and non-reactive, the entrapped products are stable at room temperatures and require no refrigeration of any kind.
- Figure 1 shows differential scanning calorimetry of a 50 / 50 w/w mannitol / calcium lactate glass showing a clear glass transition at a temperature of 68 °C;
- Figure 2 shows differential scanning calorimetry of a 50 / 50 w/w trehalose / calcium lactate glass showing a clear glass transition at a temperature of 90 °C;
- Figure 3 shows the percentage recovery of alkaline phosphatase activity after vacuum- drying in either trehalose or formula 7 containing mannitol, inositol, galactitol and degraded gelatin (Byco C) followed by storage at 37°C or 50°C for up to 6 weeks. There is no loss with formula 7 but serious losses with trehalose;
- Figure 4 shows the percentage recovery of alkaline phosphatase activity after freeze-drying in either trehalose or formula 7 containing mannitol, inositol, galactitol and degraded gelatin (Byco C) followed by storage at 37°C or 50°C for up to 7 weeks. There is little loss with either stabiliser;
- Figure 5 shows the percentage recovery of Erythropoietin (EPO) after vacuum-drying in either trehalose or formula 8 containing mannitol, inositol, galactitol and calcium lactate followed by storage at 37°C or 50°C for up to 6 weeks. While there is serious losses with trehalose, no loss occurs with formula 8; and
- Figure 6 shows the percentage recovery of EPO after freeze-drying in either trehalose or formula 7 containing mannitol, Inositol, galactitol and degraded gelatin (Byco C) or formula 8 in which calcium lactate was substituted for the gelatin. After storage at 37°C or 50°C for 7 weeks, there is no loss with any of the stabilising formulations.
- Figure 7 shows the percentage recovery of alkaline phosphatase activity after spray drying formula 9 to which had been added insoluble calcium phosphate powder to increase the density of the glass microspheres. After storage at either 37°C or 55°C for up to 90 days there was no significant loss of activity.
- Figure 8 shows the percentage recovery alkaline phosphatase activity after spray drying formula 1 1 to which had been added insoluble barium sulphate powder to increase the density of the glass microspheres. After storage at either 37"C or 55°C for up to 90 days there was again no significant loss of activity.
- a network forming additive such as sodium or potassium tetraborate
- a network forming additive such as sodium or potassium tetraborate
- Affinity purified alkaline phosphatase from bovme intestinal mucosa (Sigma Chemical Co cat No p-8647) was vacuum-d ⁇ ed or freeze-d ⁇ ed m 200 ⁇ l volumes in formulation Number 7 above or in trehalose.
- Vacuum drying was done at a shelf temperature of 40°C and a vacuum of 30- 100 milhtorr for 4 hr The temperature was then ramped gradually to 60°C over 1 hr and the vials were stoppered and removed from the vacuum chamber for high temperature storage trials Freeze-drying was done in a Labconco dryer at an initial shelf temperature of-40°C for 3 hr at a vacuum of 30-100 milhtorr The shelf temperature was then ramped to 0°C at 5°C / mm and held for 1 hr The shelf temperature was then raised to 40°C at 5°C / min and secondary drying was continued for a further 3 hr when the vials were stoppered under vacuum and removed for storage trials
- EPO was vacuum dried or freeze-d ⁇ ed as above in the same solutions and also in a va ⁇ ant of formulation 7 in which calcium lactate was substituted for Byco C (Formula 8), and then subjected to the same stability tests before being assayed by a standard 2-s ⁇ te sandwich Enzyme Immunoassay
- the fluorescent protein R-Phycoeryth ⁇ n was air-dried in trehalose, formula 3 or formula 4 on a hotplate as described in Example 1
- the intensity of fluorescence was gauged visually when illuminated with a UV lamp.
- the material dried in formula 3 was masked by an intense silver autofluorescence from the Byco C while the material dried in formula 4 fluoresced with the characteristic orange colour with apparently undimmished intensity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9805699.7A GB9805699D0 (en) | 1998-03-18 | 1998-03-18 | New stabilising glasses |
GB9805699 | 1998-03-18 | ||
GBGB9820689.9A GB9820689D0 (en) | 1998-09-23 | 1998-09-23 | New stabilising glasses |
GB9820689 | 1998-09-23 | ||
PCT/GB1999/000820 WO1999047174A1 (en) | 1998-03-18 | 1999-03-17 | Amorphous glasses for stabilising sensitive products |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1071465A1 true EP1071465A1 (en) | 2001-01-31 |
Family
ID=26313295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99910516A Withdrawn EP1071465A1 (en) | 1998-03-18 | 1999-03-17 | Amorphous glasses for stabilising sensitive products |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1071465A1 (en) |
AU (1) | AU2945199A (en) |
WO (1) | WO1999047174A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6190701B1 (en) | 1999-03-17 | 2001-02-20 | Peter M. Ronai | Composition and method for stable injectable liquids |
GB2362555A (en) * | 2000-05-26 | 2001-11-28 | British Sugar Plc | Amorphous sugar coatings |
US6653062B1 (en) | 2000-07-26 | 2003-11-25 | Wisconsin Alumni Research Foundation | Preservation and storage medium for biological materials |
ATE450253T1 (en) * | 2000-10-13 | 2009-12-15 | Cambridge Biostability Ltd | PHARMACEUTICAL LIQUID SUSPENSIONS |
US6623762B2 (en) | 2001-02-16 | 2003-09-23 | Cambridge Biostability Ltd. | Composition and method for controlled release injections |
GB0406013D0 (en) | 2004-03-17 | 2004-04-21 | Chiron Srl | Analysis of saccharide vaccines without interference |
GB0523638D0 (en) * | 2005-11-21 | 2005-12-28 | Cambridge Biostability Ltd | Pharmaceutical device for the administration of substances to patients |
GB0918450D0 (en) | 2009-10-21 | 2009-12-09 | Innovata Ltd | Composition |
CN107340387B (en) * | 2017-06-20 | 2019-02-01 | 广东云天抗体生物科技有限公司 | A kind of preparation method of cell factor ELISA standard items |
IT201900025063A1 (en) * | 2019-12-20 | 2021-06-20 | Idi Integratori Dietetici Italiani S R L | GASTRORESISTANT COMPOSITIONS INCLUDING INOSITOL AND / OR SYLVESTRE GYMNEMA EXTRACT, THEIR PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS AND THEIR USE |
CN112538111B (en) * | 2020-12-09 | 2022-04-29 | 深圳市亚辉龙生物科技股份有限公司 | New coronavirus single-chain antibody, quality control product and preparation method |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6197229A (en) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | Stable erythropoietin preparation |
US5621094A (en) * | 1990-05-14 | 1997-04-15 | Quadrant Holdings Cambridge Limited | Method of preserving agarose gel structure during dehydration by adding a non-reducing glycoside of a straight-chain sugar alcohol |
JP3698721B2 (en) * | 1993-02-23 | 2005-09-21 | ジェネンテク・インコーポレイテッド | Excipient stabilization of polypeptides treated with organic solvents |
US5955448A (en) * | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
FR2719479B1 (en) * | 1994-05-04 | 1996-07-26 | Sanofi Elf | Stable lyophilized formulation comprising a protein: assay kit. |
CN1245957C (en) * | 1995-06-07 | 2006-03-22 | 廓德伦特控股剑桥有限公司 | Method for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby |
GB9705588D0 (en) * | 1997-03-18 | 1997-05-07 | Anglia Research Foundation | Stable particle in liquid formulations |
-
1999
- 1999-03-17 EP EP99910516A patent/EP1071465A1/en not_active Withdrawn
- 1999-03-17 WO PCT/GB1999/000820 patent/WO1999047174A1/en not_active Application Discontinuation
- 1999-03-17 AU AU29451/99A patent/AU2945199A/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO9947174A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2945199A (en) | 1999-10-11 |
WO1999047174A1 (en) | 1999-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Izutsu et al. | Decreased protein-stabilizing effects of cryoprotectants due to crystallization | |
EP1071465A1 (en) | Amorphous glasses for stabilising sensitive products | |
CA2293682C (en) | Stable particle in liquid formulations | |
RU2191003C2 (en) | Composition and method of stabilization of biological materials by drying without freezing | |
AU710039B2 (en) | Compositions in glassy phase, stabilised by a sugar | |
EP1231837B1 (en) | Preservation of sensitive biological material | |
US6313102B1 (en) | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof | |
US7153472B1 (en) | Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers | |
EP2222315B1 (en) | Stabilized factor ix formulations containing trehalose | |
JPH0853361A (en) | Freeze-dried formulations containing stable proteins and assay kits | |
Iglesias et al. | Adsorption isotherm of amorphous trehalose | |
EP0415567A2 (en) | Composition and method for stabilising organic compounds | |
EP2552410B1 (en) | Method for preserving alum adjuvants and alum-adjuvanted vaccines | |
Pisal et al. | Vacuum foam drying for preservation of LaSota virus: effect of additives | |
CA2458794C (en) | Plasticized hydrophilic glasses for improved stabilization of biological agents | |
AU4065393A (en) | Pharmaceutical compositions containing IL-6 | |
AU690143B2 (en) | Stable lyophilized thiotepa composition | |
US20230144557A1 (en) | Method of long-term preservation of chemical and biological species using sugar glasses | |
CA2301889C (en) | Water-soluble dry compositions | |
CN101991857B (en) | Stable pharmaceutical preparation and preparation method thereof | |
EP1254944B1 (en) | Dry compositions containing hydrophobic amino acid | |
EP0169700B1 (en) | Improved pharmaceutical formulations for ceftazidime | |
Hajare et al. | Foam dried composite glass: An alternative to lyophilization for stability enhancement of bendamustine hydrochloride | |
KR100857889B1 (en) | Dry ligase composition and preparation method thereof | |
HK1188936A (en) | Stabilized factor ix formulations containing trehalose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17P | Request for examination filed |
Effective date: 20001011 |
|
17Q | First examination report despatched |
Effective date: 20031201 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040414 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1034667 Country of ref document: HK |